Tag:
tesamorelin
Latest Headlines
Latest Headlines
FDA panel offers unanimous endorsement of Theratech's HIV drug
Canada's Theratechnologies took a big step forward on Thursday, winning the unanimous backing of 16 FDA panel members who recommended its new HIV drug tesamorelin for approval. Designed to treat the
Theratechnologies lands $10M milestone
The FDA has accepted Theratechnologies's NDA for tesamorelin, a treatment for excess abdominal fat in HIV patients with lipodystrophy. The acceptance triggers a $10 million milestone payment from
Theratechnologies rests on $30M upfront cushion
Theratechnologies touted its financial fitness after closing on a collaboration and licensing deal with EMD Serono, netting a $30 million upfront payment in the process. "The closing of this
Merck Serono, Theratechnologies ink $215M deal
Merck Serono has signed a deal to license the U.S. commercialization right to tesamorelin, a drug to treat excess abdominal fat in HIV patients with lipodystrophy. Theratechnologies retains rights to
Phase III data paves way for Theratechnologies’ NDA
Theratechnologies is heralding positive Phase III data for its lead program--tesamorelin--for HIV-associated lipodystrophy. After 26 weeks of treatment in the confirmatory study, researchers said
